These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 17850915)
1. Endotoxin measures in patients' sample: how valid are the results? Stadlbauer V; Davies NA; Wright G; Jalan R J Hepatol; 2007 Nov; 47(5):726-7; author reply 727-3. PubMed ID: 17850915 [No Abstract] [Full Text] [Related]
2. Is bacterial DNA a better marker than endotoxin of bacterial translocation in decompensated cirrhosis? Vlachogiannakos J; Daikos G; Thalheimer U; Burroughs AK; Ladas SD Hepatology; 2011 Jun; 53(6):2140-1; author reply 41-2. PubMed ID: 21425309 [No Abstract] [Full Text] [Related]
3. Bacterial DNA induces the complement system activation in serum and ascitic fluid from patients with advanced cirrhosis. Francés R; González-Navajas JM; Zapater P; Muñoz C; Caño R; Pascual S; Márquez D; Santana F; Pérez-Mateo M; Such J J Clin Immunol; 2007 Jul; 27(4):438-44. PubMed ID: 17404822 [TBL] [Abstract][Full Text] [Related]
4. A dextran-based warming method for preparing leukocyte-rich plasma and its clinical application for endotoxin assay. Takahashi G; Inada K; Sato K; Inoue Y Biotechniques; 2020 Jun; 68(6):300-304. PubMed ID: 32116002 [TBL] [Abstract][Full Text] [Related]
9. A new endotoxin-specific assay. Obayashi T Adv Exp Med Biol; 1990; 256():215-23. PubMed ID: 2183551 [No Abstract] [Full Text] [Related]
10. Sequential changes in plasma cytokine and endotoxin levels in cirrhotic patients with bacterial infection. Wang SS; Lee FY; Chan CC; Lu RH; Chao Y; Lin HC; Wu SL; Tsai YT; Lee SD Clin Sci (Lond); 2000 Apr; 98(4):419-25. PubMed ID: 10731475 [TBL] [Abstract][Full Text] [Related]
11. [Endotoxins in the plasma and ascitic fluid of the cirrhotic patient. Their clinical significance]. Pozzato G; Miani N; Frezza M Minerva Med; 1981 Jun; 72(24):1519-24. PubMed ID: 7243030 [TBL] [Abstract][Full Text] [Related]
12. Association of markers of bacterial translocation with immune activation in decompensated cirrhosis. Mortensen C; Jensen JS; Hobolth L; Dam-Larsen S; Madsen BS; Andersen O; Møller S; Bendtsen F Eur J Gastroenterol Hepatol; 2014 Dec; 26(12):1360-6. PubMed ID: 25357217 [TBL] [Abstract][Full Text] [Related]
13. [Studies of endotoxin in liver cirrhosis. 2. Clinical significance of the appearance of endotoxin during the cirrhotic change of the liver]. Tarao K; So K; Moroi T; Ikeuchi T; Endo O Nihon Shokakibyo Gakkai Zasshi; 1977 Jun; 74(6):748-54. PubMed ID: 561244 [No Abstract] [Full Text] [Related]
14. [Endotoxin in liver cirrhosis. 1. Endotoxin in contained the ascitic fluid in liver cirrhosis]. Tarao K; Endo O; Ikeuchi T; So K; Moroi T Nihon Shokakibyo Gakkai Zasshi; 1976 Nov; 73(11):1366-72. PubMed ID: 1034805 [No Abstract] [Full Text] [Related]
18. Portal venous and systemic endotoxaemia in patients without liver disease and systemic endotoxaemia in patients with cirrhosis. Prytz H; Holst-Christensen J; Korner B; Liehr H Scand J Gastroenterol; 1976; 11(8):857-63. PubMed ID: 794999 [TBL] [Abstract][Full Text] [Related]
19. The relationship between endotoxin and the phagocytic activity of the reticuloendothelial system. Kuratsune H; Koda T; Kurahori T Hepatogastroenterology; 1983 Jun; 30(3):79-82. PubMed ID: 6193047 [TBL] [Abstract][Full Text] [Related]